Immunomodulators: interleukins, interferons, and IV immunoglobulin

Joris J. ROELOFS¹, Daniel ABRAMOWICZ² and Sandrine FLORQUIN¹

¹Department of Pathology, Academic Medical Center, Amsterdam, The Netherlands
²Department of Nephrology, Hopital Erasme, Brussels, Belgium

Introduction 684
Pathogenesis 685
  Tubular necrosis 685
  Thrombotic microangiopathy 685
  Serum sickness 685
  Auto-immune disorders 685
Recombinant cytokines 686
  Interleukin-2 686
  Interferons 688
  Interferon-α 688
  Interferon-β 690
  Interferon-γ 690
Monoclonal antibodies 691
  Anti-CD3 antibodies 691
  Anti-CD4 691
  Anti-CD20 antibodies 691
  Anti-TNF antibodies 692
  Anti-IL-2 Receptor 692
  Anti-CD52-antibody 692
Intravenous immune globulin 693
Anti-thymocyte globulin 693
References 694
Introduction

The outstanding progress in immunology and the development of new technologies have resulted in the introduction of new immunotherapies, the so-called “immunomodulators”, for autoimmune diseases, inflammatory disorders, allograft rejection, and cancer. These immunomodulators comprise recombinant cytokines and specific blocking or depleting antibodies. Many of these therapies achieve their effect by stimulating the release of cytokines. The term cytokines includes interleukins (IL-), chemokines, growth factors, interferons (IFN), colony stimulating factors (CSF), and tumor necrosis factors (TNF). These molecules are involved in inflammation, cell proliferation and apoptosis, tissue injury and repair.

These new therapeutic tools can be associated with side effects among which nephrotoxicity. The most common immunomodulators associated with nephrotoxicity are described in Table 1. The nephrotoxic side effects of immunomodulators can be roughly divided into (ischemic) tubular necrosis, thrombotic microangiopathy, serum sickness, and autoimmune disorders.

This chapter aims to address the nephrotoxic potential of the cytokines or monoclonal antibodies at the doses being used in the treatment of cancer, autoimmune diseases, and transplantation.

| Agent               | Pharmacological substance | Indications                                      | Renal toxicity                                      | References                       |
|---------------------|---------------------------|--------------------------------------------------|-----------------------------------------------------|----------------------------------|
| Aldesleukine        | Recombinant **IL-2**      | - Metastatic renal cell carcinoma                | - Acute renal failure                               | 9, 15-18                        |
|                     |                           | - Melanoma                                       |                                                     |                                  |
| Interferon-α        | Recombinant **IFN-α**     | - Viral hepatitis                                 | - Acute renal failure                               | 27, 31, 32, 33-35, 38-40, 42-48, 51, 52, 54, 58, 59 |
|                     |                           | - Non-Hodgkin lymphoma                            | - Proteinuria                                       |                                  |
|                     |                           | - Several other malignancies                      | - Lupus-like disease                                |                                  |
|                     |                           |                                                   | - Pauci-immune GN                                   |                                  |
|                     |                           |                                                   | - RPGN                                              |                                  |
|                     |                           |                                                   | - FSGS                                              |                                  |
|                     |                           |                                                   | - Minimal change nephrotic syndrome                 |                                  |
|                     |                           |                                                   | - Allograft rejection                               |                                  |
| Peginterferon-α     | Pegylated **IFN-α**       | - Hepatitis C                                     | - Acute renal failure                               | 60, 61                           |
|                     |                           |                                                   | - Exacerbation of vasculitis                        |                                  |
| Interferon-β        | Recombinant **IFN-β**     | - Multiple sclerosis                              | - None reported                                      | 62, 63                           |
| Interferon-γ        | **IFN-γ-1b**              | - Chronic granulomatous disease                   | - Proteinuria                                       | 64, 66, 67                       |
| Muromonab (OKT3)    | Anti-**CD3** Ab           | - Allograft rejection                              | - Acute renal failure                               | 76, 78-82                        |
|                     |                           |                                                   | - Thrombotic microangiopathy                        |                                  |
| Rituximab           | Anti-**CD20** Ab          | - Rheumatoid arthritis                            | - Acute renal failure                               | 86-89                            |
|                     |                           | - Non-Hodgkin lymphoma                            | - Serum sickness                                     |                                  |
| Infliximab          | Anti-**TNFα** Ab          | - Rheumatoid arthritis                            | - Serum sickness                                     | 90-93                            |
|                     |                           | - Crohn's disease                                 | - Lupus-like disease                                 |                                  |
|                     |                           | - Ankylosing spondylitis                          | - Extracapillary glomerulonephritis                  |                                  |
| Alemtuzumab (Campath)| Anti-**CD52** Ab          | - B-cell chronic lymphocytic leukemia              | - HUS                                               | 98, 99, 101                      |
|                     |                           | - Preconditioning regimen for bone marrow and renal transplantation | - Acute renal failure                               |                                  |
|                     |                           |                                                   | - Acute humoral rejection                            |                                  |
| Intravenous immune globulin (IVIG) | Human IgG | - Primary immunodeficiency syndromes                | - Acute renal failure                               | 103, 106-108                    |
| Thymoglobulin (ATG) | Anti-thymocyte globulin   | - Acute kidney and liver allograft rejection       | - Acute renal failure                               | 110, 111                        |
Pathogenesis

Tubular necrosis

Cytokine associated renal dysfunction is regularly observed in the setting of sepsis syndrome or systemic inflammatory response syndrome. The cytokine release syndrome associated for example with OKT3 administration is similar to systemic inflammatory response syndrome. During systemic inflammatory response syndrome, it has been observed that even in the absence of systemic hypotension, acute tubular necrosis (ATN) can occur. Certain cytokines released during systemic inflammatory response syndrome mediate peripheral vasodilation in the absence of systemic hypotension. The renal response to peripheral vasodilation is vasoconstriction of the renal vasculature and reduced renal blood flow. TNF-α is a pro-inflammatory cytokine which plays a central role in the pathogenesis of systemic inflammatory response syndrome. TNF-α stimulates the secretion of IL-1β and regulates genes coding for other inflammatory mediators such as IL-1, IL-6, IL-8, and macrophage inflammatory protein (MIP-2). The major cellular sources of TNF-α are monocytes and T cells but upon injury, renal tubular cells start also to produce TNF-α as well as other pro-inflammatory cytokines [1-3] leading to an amplification of the inflammatory responses. TNF-α and IL-1 have also been shown to induce glomerular endothelial and mesangial cell production of vasoconstricting mediators like platelet activating factor (PAF), endothelin-1 (ET-1) and adenosine, but also of the vasodiators nitric oxide and prostaglandin E2. Local release of TNF-α reduces glomerular blood flow and glomerular filtration rate, induces the synthesis of other proinflammatory mediators, and, along with reactive oxygen species, increases glomerular albumin permeability. Pro-inflammatory cytokines recruit neutrophils and monocytes to the kidney and enhance their adhesion to endothelial cells.

Thrombotic microangiopathy

Thrombotic microangiopathy results from a massive activation of the clotting cascade. The major initiating factors are the release or expression of tissue factor, usually involving entry of tissue thromboplastins into the circulation, extensive injury to vascular endothelium exposing tissue factor, or enhanced expression of tissue factor by monocytes in response to endotoxin and various cytokines. Very high doses of systemic TNF can cause thrombotic microangiopathy as observed by Bertani in an experimental rabbit model. He showed that an intravenous TNF infusion did induce glomerular endothelial damage, neutrophil accumulation, and fibrin deposition within capillary lumens [4]. TNF-α induces production of reactive oxygen species by mesangial cells and tissue factor production by mesangial and endothelial cells, leading to fibrin deposition [5].

Serum sickness

The originators of the term ‘serum sickness’ are von Pirquet and Schick, who published a book with that title (Das Serumkrankheit) in 1905 [6]. The authors described an illness that developed in some patients after administration of horse serum that had been given as an antitoxin for the treatment of diphtheria and scarlet fever. Serum sickness is characterized by fever, rash, arthralgias, and eventually glomerulonephritis. Serum sickness is the prototypic example of the Coombs ‘type III’ or immune complex mediated hypersensitivity disease. The disease requires the presence of the antigen coincident with antibodies directed against the antigen, leading to the formation of antigen-antibody or immune complexes. These should normally be cleared by the mononuclear phagocyte system. If this system is not functioning well or is saturated by the immune complex load, then excess immune complexes may form in the circulation and deposit in tissues, or form directly in the involved tissues. The deposition of antigen-antibody (immune) complexes in tissues triggers the activation of the complement cascade, recruitment of leukocytes, and release of inflammatory mediators, such as histamine. Classic serum sickness can occur after injections of chimeric monoclonal antibodies but a variety of drugs can also cause reactions that clinically resemble classical serum sickness, but are believed to be caused by different mechanisms. In most cases, the specific mechanism is not known.

Auto-immune disorders

Drug-induced lupus is a syndrome which shares symptoms and laboratory characteristics with idiopathic systemic lupus erythematosus (SLE). Similarly
to idiopathic lupus, drug-induced lupus can be divided into systemic, sub-acute cutaneous and chronic cutaneous lupus. The syndrome is characterized by arthralgia, myalgia, pleurisy, rash and fever in association with antinuclear antibodies in the serum. The clinical and laboratory manifestations of drug-induced SLE are similar to those of idiopathic SLE, but central nervous system and renal involvement are rare in drug-induced lupus [7]. Blockade of TNF in human rheumatoid arthritis or Crohn’s disease led to the development of autoantibodies, lupus-like syndrome, and glomerulonephritis in some patients. These data raise concern about using TNF-blocking therapies in renal disease because the kidney may be especially vulnerable to the manifestation of autoimmune processes. Interestingly, recent experimental evidence suggests distinct roles for the 2 TNF receptors in mediating local inflammatory injury in the kidney and systemic immune-regulatory functions [8].

**Recombinant cytokines**

**Interleukin-2**

IL-2 is a 15 kilodalton glycoprotein which is normally produced by antigen or mitogen activated circulating T lymphocytes. It induces natural killer cell activity, enhances the allogeneic response, and activates cytotoxic T lymphocytes [9].

IL-2 has been used in the treatment of solid tumors such as metastatic melanoma, metastatic renal cell carcinoma, and colorectal carcinoma. Interleukin-2 infusions are associated with significant dose-dependent toxicity characterized by fevers, malaise, nausea, vomiting, diarrhea, hepatic dysfunction, pulmonary edema, somnolence, confusion, dysrhythmias, myocardial infarction, hematopoietic suppression, and renal insufficiency [10]. IL-2 has a short serum half-life of 6-10 min and a clearance of 30-60 min after bolus intravenously infusion [11]. Resultant toxicity is generally transient and reversible. It is possible that IL-2 induced renal failure only occurs in the setting of profound hypotension, prior volume depletion, concurrent administration of potentially nephrotoxic drugs, or the presence of underlying renal disease.

Morroquin et al. [12] studied the effect of high-dose IL-2 therapy in the treatment of patients with metastatic melanoma and renal cell cancer. They found that there was a subset of patients who could not tolerate high doses or retreatment due to renal toxicity. Pre-treatment factors that were significantly associated with renal toxicity were male sex, diagnosis of renal cancer, previous nephrectomy, and older age. These patients also had higher baseline creatinine.

Kozeny [13] evaluated IL-2 associated fluid and electrolyte disorders in 8 patients with metastatic cancer. All patients developed capillary leak syndrome, pre-renal azotemia, hypophosphatemia, hypocalcemia, hypomagnesemia, and respiratory alkalosis. As noted in other studies, albumin fell precipitously with an associated fall in serum calcium. However, measurement of ionized calcium and urinary calcium demonstrated true hypocalcemia and hypocalciuria. There was an associated hypomagnesemia and hypomagnesura, hypophosphatemia, hypophosphaturea. Primary hyperventilation and respiratory alkalosis were thought to have caused an increased binding to albumin and intracellular shifts of these ions. Likewise, severe hypophosphatemia can be seen in gram negative sepsis in association with respiratory alkalosis. All patients developed a compensatory metabolic acidosis due to chronic hyperventilation. Respiratory alkalosis was thought to have developed because of capillary leak into the lungs producing borderline or frank pulmonary edema. After several days a superimposed normal anion gap acidosis developed from dilution by large volumes of saline fluid resuscitation. The authors found no defects in renal handling of calcium, phosphorous, or magnesium. There was no evidence of a renal acidification defect or renal tubular acidosis.

Shalmi et al. [14] suggested that an intrinsic renal defect may contribute to the renal dysfunction since the creatinine appeared to increase out of proportion to the blood urea nitrogen. If the predominant lesions were pre-renal azotemia, one would expect relative preservation of glomerular filtration rate in the face of renal hypoperfusion, thereby increasing the filtration fraction. The urinalysis did not show an active sediment as one might see in acute tubular necrosis. The authors suggested that the generalized capillary leak syndrome associated with the administration of IL-2 might have contributed to intra-renal edema and congestion leading to increased back-pressure and a decrease in ultrafiltration pressure and glomerular filtration rate.

Vlasveld [15] obtained biopsy material from a pa-
Acute tubulo-interstitial nephritis was present on pa-
block prostaglandin-mediated glomerular afferent
 gain and edema were observed in conjuction with the
 gia’s, and malaise associated with IL-2 administration.

IFN

disease, had a serum creatinine <1.9 mg/dl (despite
development of acute renal failure. Serum creatinine re-
diminished glomerular filtration rate and evidence of

Co-administration of an NSAID with IL-2 sometimes
precipitated acute renal failure.

Beldegrun [9] studied 99 patients with various
types of metastatic cancer who had no identified renal
disease, had a serum creatinine <1.9 mg/dl (despite
unilateral nephrectomy in some) and had no autoim-

eterial vasodilation that is part of the auto-regula-
tory response to hypotension and renal hypo-perfusion.
Co-administration of an NSAID with IL-2 sometimes
precipitated acute renal failure.

Beldegrun [9] studied 99 patients with various
types of metastatic cancer who had no identified renal
disease, had a serum creatinine <1.9 mg/dl (despite
unilateral nephrectomy in some) and had no autoim-

eterial vasodilation that is part of the auto-regula-
tory response to hypotension and renal hypo-perfusion.
Co-administration of an NSAID with IL-2 sometimes
precipitated acute renal failure.
arterial blood pressure still dropped from 105 to 86 mm/Hg. Urine output dropped significantly and serum creatinine rose significantly. Urine sediment was normal on day 1 but contained multiple epithelial cells and brown casts by day 5 [22].

Others have shown that oliguria accompanying IL-2 infusions, responds to low-dose dopamine infusions, fluid resuscitation, and alpha agonists such as phentylephrine [20, 23, 24].

Rafi-Janajreh et al [25] examined the mechanism of IL-2 induced vascular leak syndrome in a mouse model. The vascular leak was especially significant in the lung and liver of wild-type mice but was markedly reduced in the lungs and liver of CD44 knockout mice. Both groups had similar levels of perivascular infiltration with lymphocytes but the CD44 knockout mice did not have endothelial cell damage and also exhibited a marked decrease in IL-2-induced lymphokine-activated killer cell activity. These investigators also showed that the vascular leak syndrome was dependent on the expression of CD44 on immune cells and not on the endothelial cells.

The above-mentioned studies have suggested or proposed a direct renal injury by IL-2, but none of them have been able to conclusively distinguish a direct IL-2 renal effect from simple renal under-perfusion severe enough to cause ischemia and ATN. The toxicity of IL-2 has been clearly associated with widespread endothelial cell damage and capillary leak [25]. This is consistent with a generalized, systemic effect of IL-2 rather than proof of a specific direct effect on the kidney.

Hall et al. [26] examined the nephrotoxic effects of IL-2 and its putative mediator, TNFα, in a pig kidney cell line. Levels of IL-2 comparable to those used in human studies, caused vacuolization, cell shrinkage and growth inhibition. Dexamethasone, which is used clinically to inhibit TNFα, failed to protect the cultured cells from the effects of IL-2. TNFα when given alone had no apparent effect on morphology or cell growth, suggesting that the nephrotoxic effect of IL-2 was direct.

Interferons

IFNα and IFNβ share 29% amino acid homology. Type I IFN (α and β) differ from Type II IFN (γ) in biochemical properties, biological function, and receptor specificity. Side effects common to both classes of IFN include chills, fever, rigors, headache, myalgia’s, hypotension, nausea, vomiting, anorexia, constipation, fatigue, neutropenia, and elevated transaminases. This constellation of symptoms frequently results in mild to moderate hypotension and volume depletion and could potentially contribute to pre-renal azotemia or ATN.

**Interferon-α**

IFNα has anti-viral and anti-proliferative effects which have proven useful in the treatment of hepatitis B and C, cryoglobulinemia, and various tumors including rectal cancer, lymphoma, breast cancer, ovarian malignancies, cutaneous T-cell leukemia (mycosis fungoides), bladder cancer, cervical dysplasia, melanoma, and chronic lymphocytic lymphoma. Side effects include fever, chills, malaise, headache, myalgia’s, neuropathy, somnolence, confusion, and fatigue. Leukopenia and elevation of serum transaminases are the most common dose limiting side effects. Nephrotoxicity is uncommon and usually noted in individual case reports as an association with administration of IFNα. Often there are other factors contributing to acute renal failure such as concomitant renal disease (nephrectomy, hepatitis C infection, or nephrotoxic drugs). Phillips reviewed this topic in 1996 [27]. Guterman [28] reported no effects of treatment on serum creatinine and blood urea nitrogen, although transient pyuria was noted in 5 of 16 patients. Abdullhay [29] noted mild elevations of blood urea nitrogen and creatinine in 10 patients and more severe dysfunction in 2 of 36 patients with ovarian malignancies. The latter 2 patients had prior renal impairment.

Reports of isolated proteinuria associated with IFNα therapy have cropped up in the literature. Sherwin [30] observed 2 patients with transient proteinuria of less than 2 g/day which recurred with rechallenge with IFNα. Quesada [31] initially reported proteinuria of less than 2 g/day which recurred with rechallenge with IFNα. In a later publication, Quesada [32] cited an overall incidence of non-dose related proteinuria in 15-20% of patients. Quantitation rarely exceeded 1 gram and was not associated with a decline in glomerular filtration rate. Ferri [33] also noted proteinuria in patients being treated for mixed cryoglobulinemia but admitted that subclinical glomerular involvement with cryoglobulins could have been present. A few cases of
acute renal failure and nephrotic syndrome have also been reported [34, 35].

As far back as 1976 IFNa was shown to be able to induce glomerulonephritis in animal models. Grefer [36] was able to develop an animal model of acute glomerulonephritis (GN) by injecting high dose IFNa into mice. Experimental evidence supports an immunologic effect of IFNα the kidney. Morel-Maroger [37] injected partially purified mouse interferon into newborn mice and found marked thickening of the glomerular basement membrane preceding the deposition of immunoglobulin and complement.

Since then there have been a number of case reports of IFNa associated GN in humans. A variety of lesions have been reported including minimal change disease, pauci-immune GN, rapidly progressive GN, and focal segmental glomerulosclerosis [38, 39]. Two studies reported the onset of a nephrotic syndrome during treatment with IFNa. The nephrotic syndrome reversed after treatment was withdrawn [34, 40]. Herman [41] published a report of a patient with hairy cell leukemia who developed mesangio-capillary GN during treatment with IFNa. He developed hematuria, pyuria, and depressed complements. Colovic reported a patient with Philadelphia chromosome positive CML and nephrotic syndrome in whom renal insufficiency developed after the onset of IFNa treatment [42]. A renal biopsy showed the characteristics of mesangio-capillary glomerulonephritis. In spite of the discontinuation of treatment, renal function deteriorated and the patient died six months after the onset of the symptoms. Averbuch [43] reported a patient with Mycosis Fungoides who developed a minimal change nephropathy and acute interstitial nephritis after 6 doses of IFNa. After IFNa was discontinued, renal function returned to normal, but low grade proteinuria persisted for 2 months. Rechallenge with IFNa again produced azotemia and nephrotic range proteinuria. The authors suggested that activated cytotoxic T cells were responsible for a cell mediated delayed hypersensitivity mechanism of injury. Similar cases of minimal change disease associated with IFNa were reported by Traynor et al [44] and Rettmar et al [45]. Shah et al reported 2 cases of renal failure associated with IFNa treatment of chronic myeloid leukemia. Both patients had proteinuria and focal segmental glomerulosclerosis on biopsy [46]. Recently, two case reports were issued that concerned the occurrence of acute renal failure in patients that were treated with IFNa for metastatic carcinoid tumors [47, 48]. In both cases, renal function recovered after cessation of therapy.

Unusual immune side-effects have also been reported in association with IFNa therapy. Chronic hemolytic uremic syndrome was observed in a patient with multiple myeloma treated with IFNa (De Bree ME, personal communication). The post bone marrow transplantation course was complicated and he received several nephrotoxic antibiotics. Three months later a treatment with IFNa was started. Towards the end of the treatment renal function deteriorated. There was partial renal recovery after cessation of therapy. Renal biopsy showed focal mesangio-capillary lesions, mesangiolysis and intracapillary thrombosis consistent with a chronic form of hemolytic uremic syndrome. Ravandi-Kashani et al. [49] and Harvey et al. [50] reported 3 other cases of HUS/TTP. Two patients developed renal failure requiring dialysis. E. coli OH157.H7 was grown from the stool of one patient.

Acute renal failure or deterioration has frequently been cited in association with IFNa treatment of hepatitis C and even hepatitis B. It is well known that hepatitis C virus infection can cause GN. Mesangio-capillary GN is the most common manifestation and biopsy specimens have shown deposition of immune complexes composed of hepatitis C virus-related antigen and cryoglobulin. The difficulty lies in distinguishing glomerulonephritis caused by hepatitis C from glomerulonephritis seen in association with IFNa therapy or from occult underlying renal disease that is exacerbated by IFNa. There have been reports of nephrotic range proteinuria and focal segmental glomerulosclerosis on biopsy in patients who are being treated with IFNa for hepatitis C [51, 52]. Gordon et al. [53] reported a case of IFNa induced exacerbation of vasculitis (rash and renal impairment in a patient with hepatitis C-associated cryoglobulinemia. Ohta et al. [54] examined 24 patients who manifested the appearance of or exacerbation of proteinuria after IFN therapy for chronic hepatitis C infection. One patient had known hepatitis C-related glomerulopathy and cryoglobulinemia and showed a good response to therapy including improved renal function and remission of proteinuria. Yamabe et al. and also Sarac et al. confirmed good responses to IFN therapy without renal deterioration in patients with hepatitis C-related glomerulonephritis [55, 56]. In Ohta’s study only 3 subjects were treated.
with IFNα, the remainder were treated with IFNβ. As was shown by Johnson [57] improvement in mesangio-capillary GN with IFNα correlated with clearance of viremia but did not correlate with remission of proteinuria. Other results were quite variable. The authors felt that absence (or minimal presence) of Hepatitis C core antigens or cryoglobulin deposits in the glomeruli indicated non-hepatitis C virus related or primary GN and that these patients might be at higher risk for exacerbation or direct injury from IFN. There was no clear explanation for which patients would benefit from or fail to respond to IFN and which patients might develop irreversible renal injury.

Renal transplant patients with hepatitis C seem to be especially susceptible to injury from IFNα. IFNα triggers renal graft rejection in a substantial number of patients, and is now considered contra-indicated in this setting [58, 59].

In recent years, pegylated IFN (peginterferon) in combination with ribavirin has shown to attain higher virological response rates in chronic hepatitis C than standard interferon. Therefore, Peginterferon-α is rapidly becoming the standard of care for chronic hepatitis C infections. Peginterferon is produced by the addition of a polyethylene glycol molecule to standard interferon alfa-2 and results in important changes in drug metabolism, with marked prolongation of its half-life. Peginterferon-α causes virtually no toxic side effects and hitherto only two case reports on renal adverse effects of this medicine have been published. Gordon described the case of a 54-year-old patient, who developed acute renal failure nine days after commencing treatment [60]. A renal biopsy showed ATN, and exacerbation of (probably pre-existent) IgA-nephropathy. After cessation of therapy, renal function was restored. In addition, Batiste described exacerbation of cryoglobulinemia-related vasculitis in one patient, following treatment of hepatitis C with peginterferon-α [61]. Symptoms included a purpuric rash, peripheral neuropathy and acute renal failure, which resolved slowly after discontinuation of peginterferon-α therapy.

In summary, other symptoms of IFNα toxicity are far more common than nephrotoxicity (fevers, chills, malaise, arthralgias, fatigue anorexia, weight loss, depression, impaired cognitive function, diminished libido, abnormal thyroid function). Nevertheless, IFNα has a complicated and important relationship to the kidney but there are many confounding factors that tend to obscure the molecular dynamics of that relationship.

Interferon-β

IFNβ has been used in the treatment of multiple sclerosis. IFNβ has been also used in combination with IFNγ because of synergistic anti-tumor effects. The combinations of IFN appear to potentiate systemic effects and cumulative toxicity compared to administration of either interferon alone. Synergistic toxicity limits the tolerated dose maximum and may also limit efficacy. Low doses of IFN-β and -γ given in combination, either by intravenous bolus or continuous infusion, do not appear to cause renal damage or dysfunction [62, 63].

The particular renal effects of IFN-β have not been specifically evaluated. Increased insensible losses via skin or the gastrointestinal tract or fluid sequestration from capillary leak and hypoalbuminemia can contribute to the development of pre-renal azotemia. Volume depletion and hypotension stimulate Angiotensin II and renal sympathetic nerves to try to maintain filtration fraction. Angiotensin II is a potent vasoconstrictor and also up-regulates the expression of growth factors and cytokines such as TGFβ, TNFα, vascular cell adhesion molecule-1 (VCAM-1), platelet derived growth factor (PDGF), basic fibroblast growth factor (bFGF) and insulin-like growth factor that are involved in renal injury and repair.

Interferon-γ

There are several subspecies of IFNγ determined by differential glycosylation. IFNγ is the most potent immunomodulator of all IFN. IFNγ is cidal to human tumor cell lines, activates monocyte/macrophages, upregulates Class II MHC expression and increases natural killer cell activity [64]. In the kidney, IFNγ regulates Class I and II MHC expression in the basal state, in response to inflammatory stimuli, and after ischemia or ischemia-reperfusion renal injury [65].

Systemic side effects are similar to those of other IFN, namely fever, chills, rigors, hypotension, confusion, disorientation, anorexia, lethargy, nausea, vomiting, diarrhea, myalgia, leukopenia, hepatotoxicity. Side effects are reversible and limited to the time of administration of the drug. Mild changes in liver
function have been observed at higher dose levels and include hypoalbuminemia. There have been no significant changes noted in blood urea nitrogen and creatinine, although a small degree of proteinuria has occasionally been observed [64, 66].

Ault [67] reported a case of acute renal failure in a 12 year old child which required temporary hemodialysis after 19 days of therapy with IFN-γ. The urinary sediment contained numerous white cells, red cells, and waxy and granular casts. Open renal biopsy revealed focal segmental glomerosclerosis in 3 of 43 glomeruli and irregular wrinkling of the capillary walls in others. A tuft adhesion to Bowman’s capsule was seen in one glomerulus. There was also diffuse tubular damage and interstitial edema consistent with acute tubular necrosis. Electron microscopy demonstrated foot process effacement. Direct immunofluorescence was negative for IgG, IgA, IgM, kappa and lambda light chains, C3, Clq, properdin, and fibrin reactive products. Renal function returned to normal after withdrawal of the drug. The authors suggested that structural distortion of the basement membrane and absence of immune complexes was evidence for direct glomerular injury by the cytokine. However the authors could not exclude prior sub-clinical focal and segmental glomerulosclerosis in the child. To support their hypothesis, the authors cited studies in newborn Swiss mice exposed to mouse interferon in which there was diffuse glomerular basement membrane wrinkling and capillary IgG and C3 deposition which progressed to focal segmental glomerulosclerosis.

Monoclonal antibodies

Monoclonal antibodies can vary tremendously in terms of isotype, construction (animal derived, chimeric, humanized, bound to toxin), ability to activate complement, binding avidity, target specificity, and whether it binds and blocks or binds and activates the receptor. Monoclonal antibodies may be directed toward soluble or membrane bound receptors or receptor ligands, tumor antigens, growth factor or their receptors. Therefore toxicity and side effects are equally variable [68].

In general, complement-binding monoclonal antibodies are more likely to cause a first dose response and cytokine release and potentially renal failure.

Monoclonal antibodies that are associated with systemic response consistent with cytokine release include:

Anti-CD3 antibodies

OKT3 is a murine monoclonal antibody recognizing the CD3 complex closely associated with the T cell receptor (TCR). The immunosuppressive properties of OKT3 are related to its ability to deplete CD3+ T cells, to induce the internalization of the CD3-TCR complexes, and to sterically inhibit residual CD3-TCR complexes [69]. The ability of OKT3 to induce multivalent cross-linking of both the TCR-CD3 complexes and the monocyte Fc receptor results in T cell and monocyte activation [70]. This is accompanied by the systemic release of pro-inflammatory cytokines including TNF-α, IFN-γ, IL-2 and IL-6 [71-75]. This leads to a cytokine release syndrome similar to systemic inflammatory response syndrome. This is associated with the development of a transient renal dysfunction [76]. In some cases renal biopsies were obtained at the time of renal dysfunction that showed only mild interstitial edema [77]. Beside the transient kidney dysfunction described above, OKT3 exerts pro-coagulant effects which can precipitate intragraft thromboses [78-82].

Anti-CD4

Anti-CD4 monoclonal antibodies have been used in the treatment of rheumatoid arthritis, psoriasis, systemic lupus erythematosus, and multiple sclerosis. First dose reactions were observed consisting of dyspnea, chills and hypotension [83].

Anti-CD20 antibodies

Rituximab, a B cell-depleting chimeric anti-CD20 monoclonal antibody, has been used with increasing frequency in the treatment of rheumatologic diseases. First dose effect was noted with rituximab (fever, rigors, hypotension) suggesting cytokine release. Some patients have experienced severe hypotension with the first two infusions [84, 85]. Recent publications reported the occurrence of serum sickness in patients with autoimmune diseases and marked hypergammaglobulinemia [86]. Also in patients suffering from hematological malignancies such as mantle cell lymphoma [87] and marginal zone B-cell lymphoma [88]
rituximab-induced serum sickness has been described. Usually, there are no, or only mild renal side effects. Recently however, Ramamoorthy presented an unusual case of a 56-year-old man, who developed intravascular hemolysis, rhabdomyolysis and acute renal failure upon treatment with rituximab for high-grade non-Hodgkin lymphoma [89].

**Anti-TNF antibodies**

Despite a good overall safety profile, anti-TNF antibodies can induce a number of adverse effects, including autoimmunity and infections. A trial in the treatment of Crohn’s disease noted infusion reactions, transient increased of anti-dsDNA antibodies, and serum sickness-like delayed hypersensitivity with retreatment. Induction of human-antichimeric-antibodies was suggested as the cause of some of the infusion reactions [90]. A prospective study in 35 patients with Crohn’s disease showed induction of ANA and anti-dsDNA autoantibodies in 53% and 35% of infliximab-treated patients [91]. A single patient showed clinical features consistent with drug-induced lupus, including the presence of ANA and anti-dsDNA autoantibodies, which quickly resolved after discontinuation of infliximab. Reports on renal adverse effects of anti-TNF antibodies are very rare. Saint Marcoux described the occurrence of crescentic GN in as few as 2 patients out of a cohort of 39 patients, treated with an anti-TNF antibody for rheumatoid arthritis [92]. A case report by Chin et al. [93] described the case of a 29-year-old Australia-born Vietnamese who presented with nephrotic syndrome. A renal biopsy showed membranous nephropathy. Symptoms attenuated after discontinuation of infliximab therapy.

**Etanercept** is a recombinant dimeric fusion protein consisting of a TNF-α receptor ligand-binding region linked to the Fc portion of human IgG, used in the treatment of rheumatoid arthritis, anklyosing spondylitis, juvenile rheumatoid arthritis and psoriasis. Since 1998, there have been reports of vasculitic adverse events, including necrotizing vasculitis and leukocytoclastic vasculitis [92]. Etanercept has relatively little renal toxicity [94]. Recently, a case report was published that described the occurrence of Henoch-Schönlein Purpura, 11 months after starting etanercept therapy for psoriasis in a 57-yr old man [95]. Purpura was accompanied by renal failure, proteinuria and hematuria with red blood cell casts. Symptoms disappeared after discontinuation of etanercept. A second case study by Stokes described onset of renal failure, 4 months after initiation of etanercept therapy for rheumatoid arthritis [96]. On renal biopsy, the diagnosis of pauci-immune crescentic GN was established.

**Anti-IL-2 Receptor**

Of note, the anti-IL-2 Receptor (alpha chain) antibodies daclizumab and basiliximab, widely studied in renal transplant recipients, did not induce cytokine release or first dose reactions [97].

**Anti-CD52-antibody**

Campath-1H is a humanized CD52-specific depleting complement-fixing cytotoxic IgG1 monoclonal antibody. CD52 antigen is located on the surface of T and B lymphocytes, natural killer (NK) cells, and less densely on monocytes. Campath-1H depletes T lymphocytes from the peripheral blood for several months. Anti-CD52-Ab is used in the treatment of chronic lymphocytic leukemia, as induction therapy in renal transplantation and as a conditioning agent for bone marrow transplantation. Recently, a limited number of studies have been published that demonstrate possible renal adverse effects of anti-CD52-Ab. Bonatti reported the occurrence of hemolytic uremic syndrome in a renal transplant patient treated with Campath-1H [98]. In addition, Osborne described the case of a 37 year old woman who developed acute renal failure and disseminated intravascular coagulation following one dose of Campath-1H and Fludarabine, in preparation for bone marrow transplantation [99]. Campath-1H was thought to be the most likely causal agent although Fludarabine alone or in combination with Campath cannot be excluded. Renal function did not recover, requiring dialysis treatment up to 9 months after onset of symptoms. Recently, in a retrospective study in 443 renal transplant patients with biopsy-proven glomerular disease, the recurrence of glomerular disease under treatment with Campath-1H was studied [100]. In this study, the recurrence of biopsy-proven glomerular disease was similar in patients induced with Campath-1H or IL-2 receptor antagonists, while patients receiving antithymocyte antibody had a borderline lower recurrence rate than patients treated...
with other induction agents (P=0.047). Hill presented the rare case of a 38-yr-old renal transplant patient, who developed severe early acute humoral rejection, resulting in allograft loss after Campath-1H induction therapy [101].

**Intravenous immune globulin**

Intravenous immune globulin (IVIG) is purified, sterile IgG derived from pooled human plasma. Stabilizing agents such as glucose, maltose or sucrose are added in high concentrations in order to prevent or reduce immunoglobulin aggregation. IVIG modulates cytokine production and down-regulates IL-1, IL-2, IL-3, IL-4, IL-5, IL-10, TNFα, and granulocyte-macrophage colony-stimulating factor (GM-CSF). However, flushing, myalgia, headache, fever, chills, wheezing, hypotension and tachycardia have been noted after the start of the infusion and have been attributed to activation of complement and the complement cascade. Reversible rises in serum creatinine occurred in 4/17 patients treated for ANCA-associated vasculitis [102].

Acute renal failure is a well-recognized but infrequent finding after IVIG treatment and is thought to be at least partly related to the high solute load-induced injury to the proximal tubule [103]. Indeed, renal biopsies from patients with IVIG-induced acute renal failure show swelling and vacuolization of proximal tubular epithelial cells, leading to obstruction of the tubular lumen [104]. Other studies have shown that intravenous immunoglobulin infusions are more likely to result in acute renal failure in the presence of underlying renal disease or with simultaneous use of certain other drugs such as non-steroidal and angiotensin-converting-enzyme inhibitors.

IVIG is increasingly used in the treatment of autoimmune nephropathies, mainly lupus-nephritis and ANCA-associated glomerulonephritis [105]. In these diseases, IVIG is reported to reduce proteinuria and improve renal function (comprehensively reviewed by Orbach et al. [105]). However, the occurrence rate of acute renal failure in patients with lupus-nephritis and ANCA-associated glomerulonephritis, treated with IVIG), seems higher than in patients with other auto-immune diseases, although prospective studies are still lacking. Generally, the injury is reversible [106, 107]. More severe acute renal failure was noted in a patient who had underlying mixed cryoglobulinemia [108].

Although acute renal failure is an infrequent complication of IVIG therapy, clinicians should monitor renal function and sucrose-containing products should be avoided, especially in older patients with preexisting renal disease, dysfunction of other organs or volume depletion.

**Anti-thymocyte globulin**

Anti-thymocyte globulin (ATG, thymoglobulin) is a polyclonal rabbit antithymocyte globulin that has been used as an immunosuppressive agent in kidney and liver transplant patients. Despite a fairly high safety profile, reported side effects of ATG include hypertension, leucopenia and ARDS [109]. Renal adverse effects are extremely rare; only two case reports describe the occurrence of acute renal failure in patients treated with ATG [110, 111]. Cessation of ATG therapy in both cases and plasmapheresis in one case resulted in full recovery.
References

1. Giroir BP, Johnson JH, Brown T, Allen GL, Beutler B: The tissue distribution of tumor necrosis factor biosynthesis during endotoxemia, J Clin Invest 1992, 90:693-698
2. Ramesh G, Reeves WB: TNF-alpha mediates chemokine and cytokine expression and renal injury in cisplatin nephrotoxicity, J Clin Invest 2002, 110:835-842
3. Leemans JC, Stokman G, Claessen N, Rouschop KM, Teske GJ, Kirschning CJ, Akira S, van der Poll T, Weening JJ, Florquin S: Renal-associated TLR2 mediates ischemia/reperfusion injury in the kidney, J Clin Invest 2005, 115:2894-2903
4. Bertani T, Abbate M, Zoja C, Corna D, Perico N, Ghezzi P, Remuzzi G: Tumor necrosis factor induces glomerular damage in the rabbit, Am J Pathol 1989, 134:419-430
5. Wang J, Dunn MJ: Platelet-activating factor mediates endotoxin-induced acute renal insufficiency in rats, Am J Physiol 1987, 253: F1283-1289
6. von Pirquet C, Schick B: Das Serumkrankheit. Edited by Leipzig, Deuticke, 1905, p
7. Sarzi-Puttini P, Atzeni F, Capsoni F, Lubrano E, Doria A: Drug-induced lupus erythematosus, Autoimmunity 2005, 38:507-518
8. Vielhauer V, Mayadas TN: Functions of TNF and its receptors in renal disease: distinct roles in inflammatory tissue injury and immune regulation, Semin Nephrol 2007, 27:286-308
9. Beldingrun A, Webb DE, Austin HA, 3rd, Steinberg SM, White DE, Linehan WM, Rosenberg SA: Effects of interleukin-2 on renal function in patients receiving immunotherapy for advanced cancer, Ann Intern Med 1987, 106:817-822
10. Rosenberg SA, Lotze MT, Muul LM, Chang AE, Avis FP, Leitman S, Linehan WM, Robertson CN, Lee RE, Rubin JT, et al.: A progress report on the treatment of 157 patients with advanced cancer using lymphpohokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone, N Engl J Med 1987, 316:889-897
11. Lotze MT, Matory YL, Rayner AA, Ettinghausen SE, Vetto JT, Seipp CA, Rosenberg SA: Clinical effects and toxicity of interleukin-2 in patients with cancer, Cancer 1986, 58:2764-2772
12. Marroquin CE, White DE, Steinberg SM, Rosenberg SA, Schwartzentruber DJ: Decreased tolerance to interleukin-2 with repeated courses of therapy in patients with metastatic melanoma or renal cell cancer, J Immunother (1997) 2000, 23:387-392
13. Kozeny GA, Nicolas JD, Creekmore S, Sticklin L, Hano JE, Fisher RI: Effects of interleukin-2 immunotherapy on renal function, J Clin Oncol 1988, 6:1170-1176
14. Shalmi CL, Dutcher JP, Feinfeld DA, Chun KJ, Saleemi KR, Freeman LM, Lynn RI, Wiernik PH: Acute renal dysfunction during interleukin-2 treatment: suggestion of an intrinsic renal lesion, J Clin Oncol 1990, 8:1839-1846
15. Vlasveld LT, van de Wiel-van Kemenade E, de Boer AJ, Sein JJ, Gallee MP, Krediet RT, Rankin EM, Hekman A, Figdor CG: Possible role for cytotoxic lymphocytes in the pathogenesis of acute interstitial nephritis after recombinant interleukin-2 treatment for renal cell cancer, Cancer Immunol Immunother 1993, 36:210-213
16. Teixtor SC, Margolin K, Blayney D, Carlson J, Doroshov J: Renal, volume, and hormonal changes during therapeutic administration of recombinant interleukin-2 in man, Am J Med 1987, 83:1055-1061
17. Dutcher JP, Fisher RI, Weiss G, Aronson F, Margolin K, Louie A, Mier J, Caliendo G, Osman JA, Eckardt JR, Ernst ML, Doroshov J, Atkins M: Outpatient subcutaneous interleukin-2 and interferon-alpha for metastatic renal cell cancer: five-year follow-up of the Cytokine Working Group Study, Cancer Sci 1997, 3:157-162
18. Negrier S, Escudier B, Lasset C, Douillard JY, Savary J, Chevreau C, Ravaud A, Mercatello A, Peny J, Mousseau M, Philip T, Tursz T: Recombinant human interleukin-2, recombinant human interferon alpha-2a, or both in metastatic renal-cell carcinoma. Groupe Francais d'Immunotherapie, N Engl J Med 1993, 338:1272-1278
19. Schomburg A, Kirchner H, Atzpodien J: Renal, metabolic, and hemodynamic side-effects of interleukin-2 and/or interferon alpha: evidence of a risk/benefit advantage of subcutaneous therapy, J Cancer Res Clin Oncol 1993, 119:745-755
20. Margolin KA, Rayner AA, Hawkins MJ, Atkins MB, Dutcher JP, Fisher RI, Weiss GR, Doroshov JH, Jaffe HS, Roper M, et al.: Interleukin-2 and lymphpohokine-activated killer cell therapy of solid tumors: analysis of toxicity and management guidelines, J Clin Oncol 1989, 7:486-498
21. Rosenstein M, Ettinghausen SE, Rosenberg SA: Extravasation of intravascular fluid mediated by the systemic administration of recombinant interleukin 2, J Immunol 1986, 137:1735-1742
22. Ponce P, Cruz J, Travassos J, Moreira P, Oliveira J, Melo-Gomes E, Gouveia J: Renal toxicity mediated by continuous infusion of recombinant interleukin-2, Nephron 1993, 64:114-118
23. Memoli B, De Nicola L, Libetta C, Scialo A, Pacchiano G, Romano P, Palmieri G, Morabito A, Lauria R, Conte G, et al.: Interleukin-2-induced renal dysfunction in cancer patients is reversed by low-dose dopamine infusion, Am J Kidney Dis 1995, 26:27-33
24. Palmieri G, Morabito A, Lauria R, Montesarchio V, Matano E, Memoli B, Libetta C, Rea A, Merola C, Correale P, et al.: Low-dose dopamine induces early recovery of recombinant interleukin-2–impaired renal function, Eur J Cancer 1993, 29A:1119-1122
25. Rafi-Janajreh AQ, Chen D, Schmits R, Mak TW, Grayson RL, Sponenberg DP, Nagarkatti M, Nagarkatti PS: Evidence for the involvement of CD44 in endothelial cell injury and induction of vascular leak syndrome by IL-2, J Immunol 1999, 163:1619-1627
26. Hall TJ, James PR, Cambridge G: Interleukin-2 nephrotoxicity assessed in vitro, Res Commun Chem Pathol Pharmacol 1991, 73:375-378
27. Phillips TM: Interferon-alpha induces renal dysfunction and injury, Curr Opin Nephrol Hypertens 1996, 5:380-383
28. Ruttenman JR, Fine S, Quesada J, Horning SJ, Levine JF, Alexanian R, Bernhardt L, Kramer M, Spiegel H, Colburn W, Trown P, Merigan T, Dziewianowski Z: Recombinant leukocyte A interferon: pharmacokinetics, single-dose tolerance, and biologic effects in cancer patients, Ann Intern Med 1982, 96:549-556
29. Abdulhay G, DiSaia PJ, Blessing JA, Creasman WT: Human lymphoblastoid interferon in the treatment of advanced epithelial ovarian malignancies: a Gynecologic Oncology Group Study, Am J Obstet Gynecol 1985, 152:418-423
30. Shenwin SA, Knost JA, Fein S, Abrams PG, Foon KA, Ochs JJ, Schoenberger C, Maluish AE, Oldham RK: A multiple-dose phase I trial of recombinant leukocyte A interferon in cancer patients, Jama 1982, 248:2461-2466
31. Quesada JR, Hawkins M, Horning S, Alexanian R, Borden E, Merigan T, Adams F, Gutterman JU: Collaborative phase I-II study of recombinant DNA-produced leukocyte interferon (clone A) in metastatic breast cancer, malignant lymphoma, and multiple myeloma, Am J Med 1984, 77:427-432
32. Quesada JR, Talpaz M, Rios A, Kuzrock R, Gutterman JU: Clinical toxicity of interferons in cancer patients: a review, J Clin Oncol 1986, 4:234-243
33. Ferri C, Marzo E, Longobardi G, Lombardini F, La Civita L, Vanacore R, Liberati AM, Gerli R, Greco F, Moretti A, et al: Interferon-alpha in mixed cryoglobulinemia patients: a randomized, crossover-controlled trial, Blood 1993, 81:1132-1136
34. Dimitrov Y, Heibel F, Marcellin L, Chantrel F, Moulin B, Hannedouche T: Acute renal failure and nephrotic syndrome with alpha interferon therapy, Nephrol Dial Transplant 1997, 12:200-203
35. Dhib M, Bakhache E, Postec E, Vanrenterghem B, Le Roy F, Azar R, Francois A, Boldron A, Amaria R, Ozenne G, Hermelin A: [Nephrotic syndrome complicating treatment with interferon alpha], Presse Med 1996, 25:1066-1068
36. Gresser I, Maury C, Tovey M, Morel-Maroger L, Pontillon F: Progressive glomerulonephritis in mice treated with interferon preparations at birth, Nature 1976, 263:420-422
37. Morel-Maroger L, Sloper JC, Vinter J, Woodrow D, Gresser I: An ultrastructural study of the development of nephritis in mice treated with interferon in the neonatal period, Lab Invest 1978, 39:513-522
38. Lederer E, Truong L: Unusual glomerular lesion in a patient receiving long-term interferon alpha, Am J Kidney Dis 1992, 20:516-518
39. Parker MG, Atkins MB, Ucci AA, Levey AS: Rapidly progressive glomerulonephritis after immunotherapy for cancer, Am J Clin Oncol 1995, 5:1740-1744
40. Selby P, Kohn J, Raymond J, Judson I, McElwain T: Nephrotic syndrome during treatment with interferon, Br Med J (Clin Res Ed) 1985, 290:1180
41. Herrman J, Gabriel F: Membranoproliferative glomerulonephritis in a patient with hairy-cell leukemia treated with alpha-Il interferon, N Engl J Med 1987, 316:112-113
42. Colovic M, Jurisic V, Jankovic G, Jovanovic D, Nikolic LJ, Dimitrijevic J: Interferon alpha sensitisation induced fatal renal insufficiency in a patient with chronic myeloid leukaemia: case report and review of literature, J Clin Pathol 2006, 59:879-881
43. Averbuch SD, Austin HA, 3rd, Sherwin SA, Antonovych T, Bunn PA, Jr., Longo DL: Acute interstitial nephritis with the nephrotic syndrome following recombinant leukocyte a interferon therapy for mycosis fungoides, N Engl J Med 1984, 310:32-35
44. Traynor A, Kuzel T, Samuelson E, Kanwar Y: Minimal-change glomerulopathy and glomerular visceral epithelial hyperplasia associated with alpha-interferon therapy for cutaneous T-cell lymphoma, Nephron 1994, 67:94-100
45. Rettmar K, Kienast J, van de Loo J: Minimal change glomerulonephritis with reversible proteinuria during interferon alpha 2a therapy for chronic myeloid leukaemia, Am J Hematol 1995, 49:355-356
46. Shah M, Jenis EH, Mookerjee BK, Schrier JR, Baer MR, Herzog GP, Wetzler M: Interferon-alpha-associated focal segmental glomerulosclerosis with massive proteinuria in patients with chronic myeloid leukemia following high dose chemotherapy, Cancer 1998, 83:1938-1946
47. Roeloffzen WW, Hospers GA, De Vries EG, Navis GJ: Renal failure after treatment with interferon alpha 2b, Anticancer Res 2002, 22:1929-1931
48. Laboudi A, Makdassi R, Choukroun G, Fournier A: [Acute renal insufficiency secondary to interferon], Nephrologie 2003, 24:181-185
49. Ravandi-Kashani F, Cortes J, Talpaz M, Kantarjian HM: Thrombotic microangiopathy associated with interferon therapy for patients with chronic myelogenous leukemia: coincidence or true side effect?, Cancer 1999, 85:2583-2588
50. Harvey M, Rosenfeld D, Davies D, Hall BM: Recombinant interferon alpha and hemolytic uremic syndrome: cause or coincidence?, Am J Hematol 1994, 46:152-153
51. Coroneos E, Petrusheska G, Varghese F, Truong LD: Focal segmental glomerulosclerosis with acute renal failure associated with alpha-interferon therapy, Am J Kidney Dis 1996, 28:888-892
52. Bellaiche G, Guettier C, Dubouct A, Ley G, Slama JL: [Nephrotic syndrome with acute renal failure due to focal segmental glomerulosclerosis in a patient treated with alpha-interferon for chronic hepatitis C], Gastroenterol Clin Biol 2000, 24:465
53. Gordon AC, Edgar JD, Finch RG: Acute exacerbation of vasculitis during interferon-alpha therapy for hepatitis C-associated cryoglobulinemia, J Infect 1998, 36:229-230
54. Ohta S, Yokoyama H, Wada T, Sakai N, Shimizu M, Kato T, Furuchi K, Segawa C, Hisada Y, Kobayashi K: Exacerbation of glomerulonephritis in subjects with chronic hepatitis C virus infection after interferon therapy, Am J Kidney Dis 1999, 33:1040-1048
55. Yamabe H, Johnson RJ, Gretch DR, Osawa H, Inuma H, Sasaki T, Kaizuka M, Tamura N, Tsunoda S, Fujita Y, et al.: Membranoproliferative glomerulonephritis associated with hepatitis C virus infection responsive to interferon-alpha, Am J Kidney Dis 1995, 25:67-69
56. Sarac E, Bastacky S, Johnson JP: Response to high-dose interferon-alpha after failure of standard therapy in MPGN associated with hepatitis C virus infection, Am J Kidney Dis 1997, 30:113-115
57. Johnson RJ, Gretch DR, Couser WG, Alpers CE, Wilson J, Chung M, Hart J, Willson R: Hepatitis C virus-associated glomerulonephritis. Effect of alpha-interferon therapy, Kidney Int 1994, 46:1700-1704
58. Rostaing L, Izopet J, Baron E, Duffaut M, Puel J, Durand D, Suc JM: Preliminary results of treatment of chronic hepatitis C with recombinant interferon alpha in renal transplant patients, Nephrol Dial Transplant 1995, 10 Suppl 6:93-96
59. Rostaing L, Modesto A, Baron E, Cisterne JM, Chabannier MH, Durand D: Acute renal failure in kidney transplant patients treated with interferon alpha 2b for chronic hepatitis C, Nephron 1996, 74:512-516
60. Gordon A, Menahem S, Mitchell J, Jenkins P, Dowling J, Roberts SK: Combination pegylated interferon and ribavirin therapy precipitating acute renal failure and exacerbating IgA nephropathy, Nephrol Dial Transplant 2004, 19:2155
61. Batisse D, Karmochkine M, Jacquot C, Kazatchkine MD, Weiss L: Sustained exacerbation of cryoglobulinemia-related vasculitis following treatment of hepatitis C with peginterferon alfa, Eur J Gastroenterol Hepatol 2004, 16:701-703
62. Schiller JH, Storer B, Willson JK, Borden EC: Phase I trial of combinations of recombinant interferons beta(ser) and gamma in patients with advanced malignancy, Cancer Treat Rep 1987, 71:945-952
63. Schiller JH, Storer B, Witt PL, Nelson B, Brown RR, Horisberger M, Grossberg S, Borden EC: Biological and clinical effects of the combination of beta- and gamma-interferons administered as a 5-day continuous infusion, Cancer Res 1990, 50:4588-4594
64. Thompson JA, Cox WW, Lindgren CG, Collins C, Neraas KA, Bonnem EM, Fefer A: Subcutaneous recombinant gamma interferon in cancer patients: toxicity, pharmacokinetics, and immunomodulatory effects, Cancer Immunol Immunother 1987, 25:47-53
65. Takei Y, Sims TN, Urmson J, Halloran PF: Central role for interferon-gamma receptor in the regulation of renal MHC expression, J Am Soc Nephrol 2000, 11:250-261
66. Sriskandand K, Garner P, Watkinson J, Pettingale KW, Brinkley D, Calman FM, Tee DE: A toxicity study of recombinant interferon-gamma given by intravenous infusion to patients with advanced cancer, Cancer Chemother Pharmacol 1986, 18:63-68
67. Ault BH, Stapleton FB, Haber L, Martin A, Roy S, 3rd, Murphy SB: Acute renal failure during therapy with recombinant human gamma interferon, N Engl J Med 1988, 319:1397-1400
68. Green MC, Murray JL, Hortobagyi GN: Monoclonal antibody therapy for solid tumors, Cancer Treat Rev 2000, 26:269-286
69. Goldstein G: Overview of the development of Orthoclone OKT3: monoclonal antibody for therapeutic use in transplantation, Transplant Proc 1987, 19:1-6
70. Van Waauwe JP, De Mey JR, Goossens JG: OKT3: a monoclonal anti-human T lymphocyte antibody with potent mitogenic properties, J Immunol 1980, 124:2708-2713
71. Abramowicz D, Schandene L, Goldman M, Crusiaux A, Vereerstraeten P, De Pauw L, Wybran J, Kinaert P, Dupont E, Toussaint C: Release of tumor necrosis factor, interleukin-2, and gamma-interferon in serum after injection of OKT3 monoclonal antibody in kidney transplant recipients, Transplantation 1989, 47:606-608
72. Chatenoud L, Ferran C, Reuter A, Legende C, Gevaert Y, Kreis H, Franchimont P, Bach JF: Systemic reaction to the anti-T-cell monoclonal antibody OKT3 in relation to serum levels of tumor necrosis factor and interferon-gamma [corrected], N Engl J Med 1989, 320:1420-1421
73. Chatenoud L, Ferran C, Legende C, Thouard I, Merite S, Reuter A, Gevaert Y, Kreis H, Franchimont P, Bach JF: In vivo cell activation following OKT3 administration. Systemic cytokine release and modulation by corticosteroids, Transplantation 1990, 49:697-702
74. Bloemena E, ten Berge UJ, Surachno J, Wilmink JM: Kinetics of interleukin 6 during OKT3 treatment in renal allograft recipients, Transplantation 1990, 50:330-331
75. Gaston RS, Deierhoi MH, Patterson T, Prastrohler E, Julian BA, Barber WH, Laskow DA, Diethelm AG, Curtis JJ: OKT3 first-dose reaction: association with T cell subsets and cytokine release, Kidney Int 1991, 39:141-148
29. Immunomodulators

76. Toussaint C, De Pauw L, Vereerstraeten P, Kinnaert P, Abramowics D, Goldman M: Possible nephrotoxicity of the prophylactic use of OKT3 monoclonal antibody after cadaveric renal transplantation, Transplantation 1989, 48:524-526

77. Batiuk TD, Bennett WM, Norman DJ: Cytokine nephropathy during antilymphocyte therapy, Transplant Proc 1993, 25:27-30

78. Abramowicz D, Pradier O, Marchant A, Florquin S, De Pauw L, Vereerstraeten P, Kinnaert P, Vanherweghem JL, Goldman M: Induction of thromboses within renal grafts by high-dose prophylactic OKT3, Lancet 1992, 339:777-778

79. Abramowicz D, Pradier O, De Pauw L, Kinnaert P, Mat O, Surquin M, Doutrelepept J, Vanherweghem JL, Capel P, Vereerstraeten P, et al.: High-dose glucocorticosteroids increase the procoagulant effects of OKT3, Kidney Int 1994, 46:1596-1602

80. Gomez E, Aguado S, Gago E, Escalada P, Alvarez-Grande J: Main graft vessels thromboses due to conventional-dose OKT3 in renal transplantation, Lancet 1992, 339:1612-1613

81. Noel C, Hazzan M, Coppin MC, Pruvot FR, Bridoux F, Lelievre G: Renal transplant artery thrombosis following treatment of allograft rejection with monoclonal anti-CD3 antibodies (OKT3), Transplant Proc 1995, 27:2438-2439

82. Shankar R, Bastani B, Salinas-Madrigal L, Sudarshan B: Acute thrombosis of the renal transplant artery after a single dose of OKT3, Am J Nephrol 2001, 21:141-144

83. Isaacs JD, Burrows N, Wing M, Keogam MT, Rebello PR, Watts RA, Pye RJ, Norris P, Hazelman BL, Hale G, Waldmann H: Humanized anti-CD4 monoclonal antibody therapy of autoimmune and inflammatory disease, Clin Exp Immunol 1997, 110:158-166

84. Gopal AK, Press OW: Clinical applications of anti-CD20 antibodies, J Lab Clin Med 1999, 134:445-450

85. Nguyen DT, Amess JA, Doughty H, Hendry L, Diamond LW: IDEC-C2B8 anti-CD20 (rituximab) immunotherapy in patients with low-grade non-Hodgkin's lymphoma and lymphoproliferative disorders: evaluation of response on 48 patients, Eur J Haematol 1999, 62:76-82

86. Finger E, Scheinberg M: Development of serum sickness-like symptoms after rituximab infusion in two patients with severe hypergammaglobulinemia, J Clin Rheumatol 2007, 13:94-95

87. Todd DJ, Helfgott SM: Serum sickness following treatment with rituximab, J Rheumatol 2007, 34:430-433

88. Schutgens RE: Rituximab-induced serum sickness, Br J Haematol 2006, 135:147

89. Ramamoorthy SK, Marangolo M, Durrant E, Akima S, Gottlieb DJ: Unusual reaction to Rituximab with intra-vascular hemolysis, rhabdomyolysis, renal failure and bone marrow necrosis, Leuk Lymphoma 2006, 47:747-750

90. Van Deventer SJ: Immunotherapy of Crohn's disease, Scand J Immunol 2000, 51:18-22

91. Nancye S, Blanvillain E, Parmentier B, Froulie B, Bayet C, Bienvenu J, Fabien N: Infliximab treatment does not induce organ-specific or nonorgan-specific autoantibodies other than antinuclear and anti-double-stranded DNA autoantibodies in Crohn's disease, Inflamm Bowel Dis 2005, 11:986-991

92. Saint Marcoux B, De Bandt M: Vasculitides induced by TNFalpha antagonists: a study in 39 patients in France, Joint Bone Spine 2006, 73:710-713

93. Chin G, Luxton G, Harvey JM: Infliximab and nephrotic syndrome, Nephrol Dial Transplant 2005, 20:2824-2826

94. Schiff MH, Whelton A: Renal toxicity associated with disease-modifying antirheumatic drugs used for the treatment of rheumatoid arthritis, Semin Arthritis Rheum 2000, 30:196-208

95. Lee A, Kasama R, Evangelisto A, Ellenbein B, Falasco G: Henoch-Schonlein purpura after etanercept therapy for psoriasis, J Clin Rheumatol 2006, 12:249-251

96. Stokes MB, Foster K, Markowitz GS, Ebrahim H, Hines W, Kaufman D, Moore B, Wolde D, D'Agati VD: Development of glomerulonephritis during anti-TNF-alpha therapy for rheumatoid arthritis, Nephrol Dial Transplant 2005, 20:1400-1406

97. Berard JL, Velez RL, Freeman RB, Tsunoda SM: A review of interleukin-2 receptor antagonists in solid organ transplantation, Pharmacotherapy 1999, 19:1127-1137

98. Bonatti H, Brandacher G, Boesmueller C, Cont M, Hengster P, Rosenkranz AR, Krugmann J, Margreiter R: Hemolytic uremic syndrome following Campath-1H induction, Transpl Int 2007, 20:386-389

99. Osborne WL, Lennard AL: Acute renal failure and disseminated intravascular coagulation following an idiosyncratic reaction to Alemtuzumab (Campath-1H) or fludarabine, Haematologica 2005, 90:ECR05

100. Pascual J, Mezrich JD, Djamali A, Leversion G, Chin LT, Torrealba J, Bloom D, Voss B, Becker BN, Knechtles SJ, Solligner HW, Pirsch JD, Samaniego MD: Alemtuzumab induction and recurrence of glomerular disease after kidney transplantation, Transplantation 2007, 83:1429-1434

101. Hill P, Gagliardi E, Ruggenenti P, Remuzzi G: Severe early acute humoral rejection resulting in allograft loss in a renal transplant recipient with Campath-1H induction therapy, Nephrol Dial Transplant 2005, 20:1741-1744

102. Jayne DR, Chapel H, Adu D, Misbah S, O’Donoghue D, Scott D, Lockwood CM: Intravenous immunoglobulin for ANCA-associated systemic vasculitis with persistent disease activity, Qjm 2000, 93:433-439

103. Gupta N, Ahmed I, Nissel-Horowitz S, Patel D, Mehrrotra B: Intravenous gammoglobin-associated acute renal failure, Am J Hematol 2001, 66:151-152
104. Cantu TG, Hoehn-Saric EW, Burgess KM, Racusen L, Scheel PJ: Acute renal failure associated with immunoglobulin therapy, Am J Kidney Dis 1995, 25:228-234
105. Orbach H, Tishler M, Shoenfeld Y: Intravenous immunoglobulin and the kidney—a two-edged sword, Semin Arthritis Rheum 2004, 34:593-601
106. Tan E, Hajinazarian M, Bay W, Neff J, Mendell JR: Acute renal failure resulting from intravenous immunoglobulin therapy, Arch Neurol 1993, 50:137-139
107. Kobosko J, Nicol P: Renal toxicity of intravenous immunoglobulin, Clin Nephrol 1992, 37:216-217
108. Barton JC, Herrera GA, Galla JH, Bertoli LF, Work J, Koopman WJ: Acute cryoglobulinemic renal failure after intravenous infusion of gamma globulin, Am J Med 1987, 82:624-629
109. Walton GD, Gualtieri RJ: Antithymocyte globulin-induced adult respiratory distress syndrome, Arch Intern Med 1998, 158:1380
110. Busani S, Rinaldi L, Begliomini B, Pasetto A, Girardis M: Thymoglobulin-induced severe cardiovascular reaction and acute renal failure in a patient scheduled for orthotopic liver transplantation, Minerva Anestesiol 2006, 72:243-248
111. Levine JM, Lien YH: Antithymocyte globulin-induced acute renal failure, Am J Kidney Dis 1999, 34:1155